全科医生药物警戒网络提供药物信息的兴趣：法国的一项比较研究。
Interest of a general practitioner pharmacovigilance network to provide drug information: A comparative study in France.
机构信息
Inserm UMR 1027, CIC Inserm 1436, service de pharmacologie médicale et clinique, laboratoire de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, Pharmacopôle, faculté de médecine de Toulouse, centre hospitalier universitaire, 37, allées Jules-Guesde, 31000 Toulouse, France.
Inserm UMR 1027, CIC Inserm 1436, service de pharmacologie médicale et clinique, laboratoire de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, Pharmacopôle, faculté de médecine de Toulouse, centre hospitalier universitaire, 37, allées Jules-Guesde, 31000 Toulouse, France.
出版信息
Therapie. 2020 Nov-Dec;75(6):617-622. doi: 10.1016/j.therap.2020.04.003. Epub 2020 Apr 22.
INTRODUCTION
Since 2015, Toulouse University PharmacoVigilance Center (TUPVC) set up a pharmacovigilance (PV) general practitioner (GP) network, called PharmacoMIP-MG. A clinical research assistant (CRA) moves to the office of GPs included in the PharmacoMIP-MG network (PMIP-GPs). There, he collects the adverse drug reaction (ADR) reports and drug-related questions. This additional support is not available to GPs not included in the PV network (NoPMIP-GPs) who have to ask drug questions spontaneously to the TUPVC.
OBJECTIVE
The objective of this study was to compare the number and characteristics of drug questions between PMIP-GPs and NoPMIP-GPs.
METHODS
All questions asked by GPs to the TUPVC from 01 Jan 2015 to 31 Dec 2017 were reviewed. Questions were classified into two groups: "general" and "related to a patient". The "related to a patient" category was divided in three subgroups: "ADRs", Drug-Drug Interactions and "Drug Management". Drugs were classified according to anatomical therapeutic chemical (ATC) classification. For comparisons, Wilcoxon test, Chi test or Fisher test were used.
RESULTS
During the study period, the CRA collected 293 questions from the 165 PMIP-GPs. TUPVC received 333 questions asked spontaneously by the 3400 NoPMIP-GPs. PMIP-GPs asked significantly 3 times more questions than NoPMIP-GPs. Most of the GP questions were classified in the "related to a patient" category (74.9%). When we compared the proportion of "related to a patient" to "general" questions, there was no statistically significant difference between PMIP-GPs and NoPMIP-GPs. PMIP-GPs asked more questions about "ADRs", but less on "Drug Management" and or "Drug-Drug Interactions". The drugs most frequently involved were amiodarone, rivaroxaban and levothyroxine.
CONCLUSION
This is the first study about GPs' drug-related questions asked to a PV center. We found that an organization, such as a CRA-GP "face to face" visit, increased the number of drug questions. This kind of organization should be developed in order to improve independent drug information outreach.
简介
自 2015 年以来，图卢兹大学药物警戒中心（TUPVC）设立了一个药物警戒（PV）全科医生（GP）网络，称为 PharmacoMIP-MG。一位临床研究助理（CRA）搬到 PharmacoMIP-MG 网络（PMIP-GPs）中包含的全科医生办公室。在那里，他收集药物不良反应（ADR）报告和与药物相关的问题。这种额外的支持不适用于未纳入 PV 网络的全科医生（NoPMIP-GPs），他们必须向 TUPVC 自发提出药物问题。
目的
本研究旨在比较 PMIP-GPs 和 NoPMIP-GPs 之间药物问题的数量和特征。
方法
回顾了 2015 年 1 月 1 日至 2017 年 12 月 31 日期间全科医生向 TUPVC 提出的所有问题。问题分为两组：“一般”和“与患者相关”。“与患者相关”类别分为三个亚组：“ADR”、药物相互作用和“药物管理”。药物根据解剖治疗化学（ATC）分类进行分类。为了进行比较，使用了 Wilcoxon 检验、卡方检验或 Fisher 检验。
结果
在研究期间，CRA 从 165 名 PMIP-GPs 中收集了 293 个问题。TUPVC 收到了 3400 名 NoPMIP-GPs 自发提出的 333 个问题。PMIP-GPs 提出的问题是 NoPMIP-GPs 的 3 倍。大多数全科医生的问题被归类为“与患者相关”类别（74.9%）。当我们比较“与患者相关”与“一般”问题的比例时，PMIP-GPs 和 NoPMIP-GPs 之间没有统计学上的显著差异。PMIP-GPs 询问了更多关于“ADR”的问题，但关于“药物管理”和/或“药物相互作用”的问题较少。涉及的药物最常是胺碘酮、利伐沙班和左甲状腺素。
结论
这是第一项关于全科医生向药物警戒中心提出的与药物相关问题的研究。我们发现，一种组织形式，如 CRA-GP“面对面”访问，增加了药物问题的数量。应该发展这种组织形式，以改善独立的药物信息传播。
Zotero 插件